The Asia-Pacific map covers 14 national systems with different product databases, pharmacy records, import controls, languages, and online-supply rules. Taiwan, Hong Kong, and Vietnam add distinct public product, institution, dealer, and supply checks. This map is a routing layer to the correct official record, not a regional legal opinion.
A product can appear under the same ingredient name across several Asia-Pacific markets while authorization, presentation, sponsor, prescription status, import route, and seller authority differ. Cross-border availability therefore cannot be inferred from a neighboring country or a global shipping page.
Use the same sequence in every country, while allowing the authority, terminology, available fields, and legal route to change.
Use the linked NMPA, TGA, Medsafe, CDSCO, PMDA, MFDS, Thai FDA, BPOM, TFDA, Hong Kong Drug Office, DAV, HSA, Philippine FDA, or NPRA record for the exact jurisdiction. Match the product identity and current status before looking at availability claims.
Where a separate pharmacy, establishment, importer, or online-supply register exists, match the legal identity and address behind the website instead of relying on branding or a regional warehouse claim.
Personal import, named-patient, special-access, prescription, and ordinary commercial supply are different routes. Use the country guide to locate the relevant rule and avoid transferring one country's exception to another.
These answers preserve the country boundary and point to the source map below. They are not medical or legal advice.
No. A seller's authority, product status, import route, and delivery claim must be checked in each destination market. A valid record in one country does not establish authorization or lawful supply in another.
Choose the destination country below and begin with its first linked product database. Then open the separate pharmacy, establishment, importer, or supply record identified by that guide before evaluating any commercial claim.
No. The map is limited to identity, status, and verification routes. Medical suitability, dosing, interactions, and safety require a qualified clinician and cannot be inferred from a product listing, registry match, or regional comparison.
These direct answers resolve the identity and status lane first. Select a destination country before drawing any conclusion about authorization, supply, or a seller.
KPV in Asia-Pacific is tracked as an FDA-reviewed unapproved peptide identity with preclinical evidence and no identified human administration study. This is not a region-wide authorization, availability, benefit, safety, or supply finding. Choose a destination country and verify its exact product and seller records.
BPC-157 in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
TB-500 in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
GHK-Cu in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Semax in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Melanotan II in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
MOTS-c in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Tesamorelin in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
AOD-9604 in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Ipamorelin in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Selank in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
PT-141 / Bremelanotide in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
CJC-1295 no DAC in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
CJC-1295 DAC in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Retatrutide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Mazdutide has NMPA approvals in China, while status, presentation, market availability, and seller authority remain jurisdiction-specific across Asia-Pacific. Choose the destination country and verify its exact records.
Ecnoglutide has NMPA approvals in China, while status, presentation, market availability, and seller authority remain jurisdiction-specific across Asia-Pacific. Choose the destination country and verify its exact records.
Enicepatide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Eloralintide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Cagrilintide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Petrelintide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
CagriSema in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
MariTide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Survodutide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
VK2735 in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Pemvidutide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Amycretin / Zenagamtide in Asia-Pacific refers to an investigational clinical program. It is not an approved product for sale, and seller-labelled material cannot inherit the sponsor's evidence or status.
Tirzepatide in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
Orforglipron / Foundayo in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
Semaglutide has product-specific approvals in some jurisdictions, not one transferable worldwide authorization for Asia-Pacific. Verify the exact brand, indication, presentation, prescription route, market status, and seller in the destination country.
DSIP / Emideltide in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
IGF-1 LR3 in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Kisspeptin-10 / KP-10 in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Melanotan I in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
NAD+ in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Sermorelin in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
Thymosin Alpha-1 in Asia-Pacific is tracked here as a US research-market identity, not a region-wide authorization or supply finding. Choose a destination country and verify the exact product and seller records there.
EGRIFTA WR in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
Liraglutide in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
SCENESSE in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
VYLEESI in Asia-Pacific begins with a US FDA identity reference only. Verify the exact product, presentation, current market status, prescription route, and seller authority in the destination country's records.
Open the first source for the product question and the second source for the seller, pharmacy, establishment, or supply question. Read the full country guide for the exact boundary.
本指南面向在中国搜索肽类、多肽药物、减重药物和研究材料的用户，提供以国家药品监督管理局药品数据和国家企业信用信息公示系统为起点的核验路径。它将具体药品批准、批准持有人、剂型规格、企业登记和网络供应声明分开处理，避免把名称相同、中文页面、人民币价格或境内发货承诺误当成产品已经获批或卖方已经验证的证据。
An Australia-specific guide to separating ARTG-listed or registered therapeutic goods, practitioner and pharmacy services, personal imports, and research-only listings before comparing cost.
A New Zealand guide to checking peptide offers against Medsafe's May 2026 consumer warning, the consent-to-market database, and the national pharmacy licence register.
An India-specific guide to using CDSCO approval and quality-alert records before treating a peptide name, clinic claim, imported listing, or laboratory document as verified evidence.
日本でペプチド、ペプチド医薬品、減量薬、研究用材料を検索する人のために、PMDAの承認品目情報、電子添文、審査報告書、安全性情報を確認する手順をまとめたガイドです。一般名が一致するだけで承認製品、販売主体、供給経路まで同一と判断せず、英訳資料と最新の日本語記録の役割も分けて扱います。
대한민국에서 펩타이드, 펩타이드 의약품, 체중 관리 약물, 연구용 물질을 검색할 때 식품의약품안전처 의약품 허가 데이터와 건강보험심사평가원 병원·약국 찾기를 이용하는 검증 가이드입니다. 국내 상품, 수입품, 병원 서비스, 연구용 표시를 같은 범주로 합치지 않고 제품과 기관의 공식 기록을 분리해 확인합니다.
คู่มือภาษาไทยสำหรับตรวจสอบการค้นหาเปปไทด์ ยาเปปไทด์ ยาควบคุมน้ำหนัก และวัสดุวิจัย โดยใช้ฐานข้อมูลทะเบียนยากับข้อมูลสถานที่ขายยาและใบอนุญาตที่ยังมีสถานะใช้งานของสำนักงานคณะกรรมการอาหารและยา ก่อนเปรียบเทียบข้อเสนอจากคลินิก ร้านขายยา สินค้านำเข้า เครื่องสำอาง หรือผู้ขายวัสดุห้องปฏิบัติการ
Panduan Indonesia untuk mencocokkan klaim produk terkait peptida di Cek BPOM dan memeriksa bukti distribusi farmasi yang tersertifikasi, masih berlaku, atau telah dicabut melalui catatan CDOB publik sebelum menilai penjual, produk impor, pasar daring, bahan riset, atau jalur pasok.
A Singapore guide to checking peptide-related offers through HSA's therapeutic-product register, licensed dealer and retail-pharmacy searches, and e-pharmacy requirements.
A Philippines guide to checking the exact peptide-related product and the establishment behind it through the FDA Verification Portal and its current regulatory records.
A Malaysia guide to checking peptide-related products in NPRA's QUEST3+ search, matching the MAL registration number, and separating product and supplier licensing claims.
本指南提供台灣胜肽、胜肽藥品、減重藥物與研究材料的逐步查證方式。先在衛生福利部食品藥物管理署許可證資料庫核對特定產品，再以衛生福利部醫事查詢系統確認藥局或醫療機構目前是否開業，避免把相同名稱、繁體中文頁面或新台幣價格誤當成核准與合法供應的證明。查證時應保留許可證字號、機構代碼、法定名稱、地址與查詢日期，讓每項網路聲明都能回到可重複檢查的紀錄。
本指南協助在香港搜尋肽類、肽類藥物、體重管理藥物或研究材料的人，利用衞生署藥物辦公室的註冊藥劑製品資料庫和持牌藥物銷售商搜尋，分別確認指定產品及法律銷售實體。網上名稱、港幣標價或本地送貨聲明都不是完整核實。核實時應記錄註冊編號、牌照類別、法定公司名稱、地址和查詢日期，讓每項供應聲明都能連回現行官方紀錄。
Hướng dẫn dành cho người tìm peptide, thuốc peptide, thuốc kiểm soát cân nặng hoặc vật liệu nghiên cứu tại Việt Nam. Bắt đầu bằng dữ liệu giấy đăng ký thuốc của Cục Quản lý Dược, sau đó kiểm tra thông tin cơ sở bán buôn hoặc đường cung ứng liên quan thay vì xem tên hoạt chất, trang tiếng Việt hay báo giá bằng đồng Việt Nam là bằng chứng đầy đủ.
Peptide Local will publish regional commercial comparisons only when every row has a sourced seller category, product status, destination market, comparable price, evidence route, and observation date. The current page compares official verification paths.